股票市场概览 港股市场表现 美股市场表现 | 2025 年 6 | 月 | 10 | 日 | | | --- | --- | --- | --- | --- | | 资讯日报 | | | | | | 海外市场主要股市上日表现 | | | | | | | | | | 升跌（%） | | 指数名称 | 收市价 | 单日 | 年内 | | --- | --- | --- | --- | | 恒生指数 | 24,181 | 1.63 | 20.55 | | 恒生国企 | 8,780 | 1.74 | 20.44 | | 恒生科技 | 5,433 | 2.78 | 21.60 | | 美国道琼斯 | 42,762 | (0.00) | 0.51 | | 美国标普 500 | 6,006 | 0.09 | 2.11 | | 美国纳斯达克 | 19,591 | 0.31 | 1.45 | | 德国 DAX | 24,174 | (0.54) | 21.42 | | 法国 CAC | 7,791 | (0.17) | 5.56 | | 英国富时 100 | 8,832 | (0.06) | 8.07 | | 日本日经 225 ...

Group 1 - The core viewpoint is that the pharmaceutical sector is experiencing a phase of revaluation, particularly in innovative drugs, which is expected to continue in the long term [2][3][4] - The market has fully recognized the pessimistic expectations for the pharmaceutical sector, influenced by economic downturns and regulatory pressures, but it overlooks the innovation and technological aspects of the industry [3][4] - The Hang Seng Medical ETF (513060) tracks the Hang Seng Healthcare Index, which consists of 70% innovative drugs and their supply chain, indicating a focus on the recovery of innovative drug valuations and cyclical recovery [4] Group 2 - In the short term (1-3 months), the pharmaceutical index is expected to enter a phase of volatility, with a consensus on the revaluation of innovative drugs [2] - In the medium term (3-12 months), the outlook for the pharmaceutical index remains optimistic, as it is currently at a low valuation compared to historical levels [2][3] - The recovery potential for cyclical aspects of the pharmaceutical sector, such as medical devices and consumer healthcare, is significant as the economy stabilizes [3][4]

2025.06. 09 本文字数：2444，阅读时长大约4分钟 作者 | 第一 财经 王方然 创新药板块再度走强。6月9日，常山药业（300255.SZ）、舒泰神（300204.SZ）、睿智医药 （300149.SZ）、众生药业（002317.SZ）等多只A股涨停。港股的金斯瑞生物科技 （01548.HK）、四环医药（00460.HK）、诺诚健华（09969.HK）等大涨超10%。 记者注意到，这轮"吃药"行情与过往不同，涨幅龙头集中于创新药企业，且港股表现尤为强劲。 爆发并非偶然，而是政策、业绩与资金面多重因素共振的结果。不过，也有机构认为火热行情下暗藏 波动风险，提醒港股短期或面临获利回吐压力。 截至当日收盘，恒生创新药ETF（159316）、港股通医药ETF（513200）分别上涨4.08%、 4.25%。多只个股涨幅较大。当日盘中，三生制药（01530.HK）股价一度涨超10%，最高触及 22.5港元，距离7年前22.631港元的历史高点仅一步之遥。自今年2月以来，三生制药股价从6港元 的位置一路暴涨，涨幅超过260%。金斯瑞生物科技、四环医药、诺诚健华等涨超10%，信达生物 （01801.HK）、康 ...

Market Overview - The Hong Kong stock market experienced a strong opening and closed with the Hang Seng Index up by 1.63% following talks between China and the U.S. [1] - The U.S. faced significant unrest due to large-scale immigration raids, highlighting underlying tensions related to various political and social issues [1] Rare Earth Market - China has shown goodwill by issuing licenses to several U.S. companies ahead of trade talks, which could expedite the approval process if negotiations proceed smoothly [2] - China's total goods trade value for the first five months reached 17.94 trillion yuan, a year-on-year increase of 2.5%, with exports growing by 7.2% [2] - In May, China's rare earth exports surged by 22.57% month-on-month, reaching 5,864.6 tons, marking a yearly high [2] - The stock of China Rare Earth (00769) rose over 60% due to these developments [2] Pharmaceutical Sector - The pharmaceutical sector saw renewed interest, driven by the upcoming American Diabetes Association (ADA) conference, which will showcase advancements in diabetes treatment, particularly GLP-1 drugs [3] - Notable stocks in this sector, such as 3SBio (01530) and Innovent Biologics (01801), experienced gains exceeding 6% [3] - The stock of King’s Ray (01548) surged over 16%, while the stock of Eucure Biopharma (09969) rose nearly 12% following positive developments in their product pipeline [3] AI Applications - Kuaishou (01024) announced a significant partnership with Lovart, enhancing its AI capabilities, which has led to a stock increase of over 5% [4] - The rapid development of AI applications is expected to positively impact cloud services, with companies like Kingdee International (00268) and Kingsoft Cloud (03896) seeing stock increases of over 9% [4] Consumer and Retail Sector - Companies like Blokko (00325) and Mijia Group (02097) were added to the Hong Kong Stock Connect list, with Blokko's stock rising over 22% due to its leading market position in the toy sector [5] - Meituan (03690) launched a drone delivery service in Hong Kong, contributing to a stock increase of 4.73% [5] Solar Industry - The upcoming SNEC PV&ES International Solar Energy Exhibition is expected to attract significant attention, although the industry faces challenges such as low prices for polysilicon [5][6] - Stocks like GCL-Poly Energy (03800) and Flat Glass Group (06865) saw increases of over 6% and 4%, respectively, amid hopes for industry recovery [6] Policy and Regulation - A press conference scheduled for June 10, 2025, will address policies aimed at improving people's livelihoods, which may impact various sectors including healthcare and insurance [7] - Companies in the healthcare sector, such as China Resources Medical (01515) and MicroPort Scientific (00853), are expected to benefit from these policy discussions [7] Company-Specific Developments - China Biologic Products (01177) presented promising data on its TQB2102 drug at the ASCO annual meeting, which is expected to boost revenue [8] - The company has received FDA approval for its innovative drug, marking a significant milestone in its product pipeline [9] - With a projected revenue growth of 21.9% in 2024, the company is well-positioned for continued expansion in the pharmaceutical market [9]

Core Viewpoint - The current "medication" market rally is distinct from previous ones, with leading gains concentrated in innovative pharmaceutical companies, particularly strong performance in the Hong Kong stock market [1][2] Group 1: Market Performance - On June 9, both Hong Kong and A-share innovative pharmaceutical sectors saw significant gains, with the Hang Seng Innovative Drug ETF rising by 4.08% and the Hong Kong Stock Connect Medical ETF increasing by 4.25% [3] - Notable individual stock performances included 3SBio (01530.HK) reaching a peak of 22.5 HKD, just shy of its historical high, and a 260% increase in its stock price since February [3] - The A-share innovative drug index rose by 31.5% and the Hong Kong innovative drug index surged by 61.54% since April 9, with several stocks doubling in value [4] Group 2: Catalysts for Growth - The surge in innovative drug stocks is attributed to multiple factors, including recent approvals for 11 innovative drugs from eight companies and promising clinical data for major diseases [5] - The upcoming 2025 ASCO annual meeting will feature 73 research studies from China, a 30% increase from the previous year [5] Group 3: Long-term Positive Factors - Many leading companies are approaching breakeven points, with significant revenue growth reported, particularly for Ascentage Pharma (332.31% growth) [7][8] - The overseas licensing deals have seen substantial increases, with a record-breaking deal of 6.05 billion USD for 3SBio's drug rights to Pfizer [9] - The overall licensing-out transactions in the innovative drug sector have surged, with 41 transactions in Q1 2024 alone, totaling 36.93 billion USD [9] Group 4: Policy Support - Recent policy changes are favorable for innovative drug companies, including optimized centralized procurement policies and increased support for innovative drugs in government reports [10] - The 2024 government work report includes 38 new innovative drugs in the medical insurance catalog, the highest ever, with plans for further optimization in 2025 [10] Group 5: Market Outlook - The valuation of the pharmaceutical sector remains relatively safe compared to other growth industries, with a current TTM P/E ratio of 27.1 times [11] - Some analysts suggest that the innovative drug sector is transitioning from following to leading in the global market, indicating a new era for domestic innovation [11] - However, there are concerns about potential short-term volatility due to rapid price increases and profit-taking by investors [11]

Group 1 - The A-share and Hong Kong stock markets have shown significant gains, with the A-share innovation drug index rising by 31.5% and the Hong Kong innovation drug index increasing by 61.54% since April 9 [2][7] - Multiple Hong Kong innovation drug ETFs have seen year-to-date gains exceeding 50%, with the Hang Seng Innovation Drug ETF and Hong Kong Innovation Drug ETF both surpassing 55% [4][6] - The recent performance of innovation drugs is attributed to the internationalization of Chinese pharmaceutical companies, highlighted by a $60 billion licensing agreement between a domestic company and Pfizer [7] Group 2 - The recent ASCO annual meeting showcased a record number of Chinese new drugs, with 74 research abstracts accepted, indicating a strong presence in the global pharmaceutical landscape [7] - Analysts predict a recovery in the CRO/CDMO sector due to improving overseas financing conditions, with a focus on integrated CROs and domestic preclinical CROs [8] - The innovation drug sector is expected to maintain its growth trajectory, supported by policy backing and increasing global competitiveness, with a potential recovery in domestic demand anticipated for 2025 [8]

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive returns in various time frames [1] - The latest net value of the fund is 2.7270 yuan, with a growth of 1.79% [1] - The fund's performance over the past month has yielded a return of 8.91%, ranking 96 out of 1025 in its category [1] - Over the last six months, the fund has achieved a return of 13.01%, ranking 146 out of 989 [1] - Year-to-date, the fund has returned 19.66%, ranking 96 out of 999 [1] Group 2 - The top ten holdings of the fund account for a total of 39.79%, with significant positions in companies such as Heng Rui Pharmaceutical (8.90%) and WuXi AppTec (5.12%) [1] - The fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan [1] - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [2]

关注创新药行情全面扩散下的投资机会 证 券 研 究 报 告 2025下半年医药生物行业投资策略 证券分析师：张静含 A0230522080004 2025.6.9 投资案件 一改颓势，医药板块上半年表现亮眼 -15% -10% -5% 0% 5% 10% 15% 20% 25% 2025/01/02 化学制药 生物制品 医疗器械 医药商业 中药 医疗服务 年初至今医药及大盘涨跌幅对比 年初至今医药二级板块涨跌幅对比 -10% -8% -6% -4% -2% 0% 2% 4% 6% 8% 10% 25/01 25/02 25/03 25/04 25/05 25/06 相对全A涨跌幅 医药生物(申万) 万得全A(除金融、石油石化) www.swsresearch.com 证券研究报告 2 ◼ 年初至6/5，医药生物（申万）指数年初至今累计涨跌幅为+8.0%，同期万得全A（除金融石油石化）涨跌幅为 +2.7%，相对大盘涨跌幅为+5.2%，在申万一级行业中排名第5。从二级行业行情表现来看，年初至今涨跌幅排名分 别为：化学制药（35.0x→41.6x）、生物制品（29.8x→41.6x）、医疗器械（30.3x→34.7 ...

Investment Rating - Investment Rating: Positive [2] Core Insights - The pharmaceutical and biotechnology industry index increased by 3.36%, ranking 6th among 31 primary industries, outperforming the CSI 300 index, which decreased by 0.21% [5][17] - The valuation of the pharmaceutical and biotechnology industry as of June 6, 2025, is 28.24x (TTM, excluding negative values), up from 27.60x in the previous period, indicating an upward trend but still below the average [5][23] - Notable sub-industry performance includes chemical preparations and other biological products, with increases of 5.77% and 4.68% respectively, while offline pharmacies saw a decline of 1.15% [5][17] Industry Review - The report highlights three major investment opportunities: 1) Companies with dual-antibody/multi-antibody technology platforms that have differentiated target design capabilities and clinical advancement efficiency are likely to attract international giants [9] 2) Areas with unmet clinical needs, such as advanced liver cancer and non-small cell lung cancer, are promising for dual-antibody therapy development [9] 3) Potential license-out candidates, as domestic innovative pharmaceutical companies continue to engage in global collaborations [9] Important Industry News - CDE launched the "Star Plan" to encourage the development of pediatric anti-cancer drugs, addressing significant unmet clinical needs in this area [7][32] - Alcon's dry eye medication "Tryptyr" received FDA approval, marking it as the first of its kind globally [39] - Hansoh Pharmaceutical's third-generation EGFR-TKI "Amivantamab" was approved in the UK for first-line treatment of NSCLC, becoming the first domestically developed EGFR-TKI approved overseas [42] - BMS and BioNTech entered a collaboration for the dual-antibody candidate BNT327, with an upfront payment of $1.5 billion and potential milestone payments of $7.6 billion [51] Company Dynamics - Stone Pharmaceutical is negotiating three potential deals totaling $5 billion, involving several products including EGFR ADCs [49] - BMS's "Rotecip" was approved for treating lower-risk myelodysplastic syndromes, marking a significant innovation in this therapeutic area [45] - AbbVie’s JAK inhibitor "Upadacitinib" was approved for treating giant cell arteritis, becoming the first approved treatment for this condition in China [48]

6月9日，中美经贸磋商会议在伦敦举行，市场风险情绪升温。 港股三大指数全天表现强势，恒生科技指数一度大涨3.2%，收涨2.78%；恒指涨1.63%站上24100点上方，从4月低点上涨21%进入技术性牛市，近乎收复此 前调整跌幅。 | 名称 | | 最新价 | 涨跌额 涨跌幅 | | --- | --- | --- | --- | | 恒生科技指数 | Fryst | 5433.23 | +146.71 +2.78% | | 800700 | | | | | 恒生指数 | Mar | 24181.43 | +388.89 +1.63% | | 800000 | | | | | 国企指数 | | 8780.13 | +150.38 +1.74% | | | M.N | | | 盘面上，大型科技股、大金融股、中字头股等权重集体表现活跃助力大市走强；医药板块大涨，创新药概念股涨幅居前；新消费概念股再度活跃，泡泡玛特 再创历史新高，半导体股、苹果概念股、军工股、稳定币概念股、石油股、教育股等热门板块齐涨。另一方面，市场避险情绪降温致金价下滑，黄金股逆势 下跌，铝、铜等有色金属股集体跟跌，啤酒股、汽车股、煤炭股普遍弱势。 ...